Skip to content Skip to footer
Subscribe Now
TOP 20

Top 20 Prescription Drugs of 2026

Shots:  Mounjaro/Zepbound, Keytruda, and Dupixent emerged among the leading prescription drug products in 2025, generating $36.51B, $31.68B, and $18.48B, respectively. Strong patient demand, expansion across approved indications, broader access, market-share gains, and new clinical and regulatory milestones continued to shape the performance of the leading prescription therapies  The global prescription drugs market was valued at…
September 11, 2026

Read more

Astrazeneca
NEWS

AstraZeneca Reports P-III OBERON and TITANIA Results for Tozorakimab in COPD at ERS’26

Shots: AstraZeneca reported full results from the P-III OBERON and TITANIA studies, showing that tozorakimab 300 mg Q4W reduced moderate-to-severe COPD exacerbations versus PBO in pts. receiving inhaled standard of care In the primary population of former smokers, tozorakimab reduced exacerbations by 29% in OBERON and 34% in TITANIA, while reductions in the overall population…
September 8, 2026

Read more

NEWS

Definium Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for DT120 in MDD

Shots: Definium Therapeutics announced that the US FDA granted BTD to DT120 (lysergide) orally disintegrating tablet (ODT) for the treatment of major depressive disorder (MDD), following positive P-III results In the P-III Emerge study, a single 100 µg dose of DT120 ODT demonstrated an 8.1-point PBO-adjusted improvement in MADRS total score at wk. 6 (p<0.0001),…
September 8, 2026

Read more

NEWS

Belite Bio Submits NDA to Japan’s MHLW for Tinlarebant in Stargardt Disease Type 1

Shots: Belite Bio submitted a New Drug Application (NDA) to Japan’s MHLW for once-daily oral tinlarebant (LBS-008) for the treatment of Stargardt disease type 1 (STGD1) The NDA was submitted under Japan’s Sakigake Designation System, following tinlarebant’s designation as a Sakigake pharmaceutical product; if approved, it could become the first approved treatment for STGD1 and…
September 8, 2026

Read more

NEWS

Novartis Reports del-desiran P-III HARBOR Study Data in Myotonic Dystrophy Type 1

Shots: Novartis announced that the P-III HARBOR study of delpacibart etedesiran (del-desiran) in people with myotonic dystrophy type 1 (DM1) did not meet its 1EP of video hand opening time (vHOT) Del-desiran showed evidence of clinical activity in 2EPs and exploratory analyses, while safety findings were generally consistent with previously reported data; Novartis is evaluating…
September 8, 2026

Read more

NEWS

Aptar and Aceso Therapeutics Collaborate to Advance Inhaled ASO Therapy for Cystic Fibrosis

Shots: Aptar Pharma and Aceso Therapeutics have entered into a collaboration to advance ACT-101, an antisense oligonucleotide (ASO) candidate designed to target underlying disease mechanisms of cystic fibrosis (CF) Aptar Pharma’s specialist inhalation development services business; Nanopharm will lead formulation development and device assessment activities to support clinical development of ACT-101 The collaboration combines Nanopharm’s…
September 8, 2026

Read more

TOP 20

Top 20 Monoclonal Antibodies of 2026 

Shots:  Keytruda, Dupixent, and Skyrizi emerged as the leading monoclonal antibody products in 2025, generating revenues of $31.68B, $18.48B, and $17.56B, respectively. Strong demand across approved indications, broader patient adoption, market share gains, and expansion into new treatment areas supported growth among the leading products  The global monoclonal antibodies market was valued at $267.6B in…
August 28, 2026

Read more

NEWS

Avricore Health’s HealthTab Enters Multi-Year Collaboration with Abbott to Expand Point-of-Care Testing Across the UK

Shots: Avricore Health’s HealthTab entered a multi-year collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products through the HealthTab platform across the UK, supporting the expansion of pharmacy-based testing. Under the agreement, HealthTab will distribute Abbott’s Afinion 2 Analyzer through NHS-linked pharmacies for HbA1c and lipid profile testing, while establishing a framework…
August 20, 2026

Read more

Load more